Navigation Links
Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies
Date:4/21/2009

of the AACR presentations. "These presentations provide additional insight into the mechanisms that act to selectively destroy the blood vessels supporting tumor growth and spread and also to reverse the ability of tumors to suppress the body's natural immune response, resulting in the mobilization of important inflammatory and other anti-tumor components of the immune system. Together, the studies provide compelling evidence suggesting that PS-targeting antibodies facilitate an important cytokine shift in the tumor environment that subsequently encourages multiple types of immune system cells to mount anti-tumor responses."

In a presentation(1) on Monday, a series of preclinical studies by a team of scientists from Peregrine Pharmaceuticals and Affitech A/S used a fully human anti-PS antibody, PGN635, to confirm previous observations that in vitro, anti-PS antibodies stimulate the tumor microenvironment to recruit monocytes and other immune cells to the tumor with resulting anti-tumor effects, most likely via cell-mediated mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC). Their data further define the role of anti-PS antibodies in mediating tumor cell cytotoxicity and the tumor microenvironment, showing that the anti-PS antibody induced a sequential release of cytokines and beta-chemokines and stimulated enhanced macrophage recruitment to tumors. Furthermore, the researchers showed that in vitro, PGN635 induced antibody-dependent death of endothelial cells, the same cell type found in the tumor vasculature, a key target of anti-PS cancer therapy. The studies also demonstrated the anti-tumor potential of PGN635 in vitro and in a number of animal cancer models.

"Data from our experiments has helped to clarify details regarding the mechanisms responsible for the anti-tumor results observed with Peregrine's PS-targeting antibodies," said Dr. Monica Friedrich, a Peregrine research scien
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
2. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
3. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
4. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
5. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
6. Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production
7. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
8. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
9. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
10. Oridion Announces Significant Medical Studies Presented at STA
11. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September ... and Chief Executive Officer, will provide an update on ... (9:55 a.m., Pacific Daylight Time).   A ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Orthopedic Instrument Industry Report, 2014-2017" report to their ... and rising proportion of reimbursement for medical expenses, the ... with its scale presenting a CAGR of 19.2% during ... three product segments of orthopedic instruments in ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and Markets ... Drug Pipeline Insight 2014" report to their offering. ... US is one of the largest segments of pharmaceuticals industry. ... rate, while the available therapies were unable to meet the ... the market for CNS disorder, especially over the past two ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2
... Scientific Corporation (NYSE: BSX ) announces results ... WATCHMAN® Left Atrial Appendage Closure (LAAC) device.  The data ... by 75 percent in patients with atrial fibrillation who ... Vivek Reddy, M.D., Director of Cardiac Arrhythmia Service at ...
... ECTE ), a company developing its needle-free ... glucose monitoring system and its Prelude® SkinPrep System for ... quarter ended March 31, 2012.  Echo,s Quarterly Report on ... through Echo,s website at www.echotx.com . ...
Cached Medicine Technology:Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy 2Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy 3Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy 4Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy 5Echo Therapeutics Announces First Quarter 2012 Financial Results 2Echo Therapeutics Announces First Quarter 2012 Financial Results 3Echo Therapeutics Announces First Quarter 2012 Financial Results 4Echo Therapeutics Announces First Quarter 2012 Financial Results 5
(Date:9/1/2014)... 01, 2014 The National Association of ... that Dawn Bazarko, DNP, MPH, RN, and Adriana Perez, ... American Academy of Nursing. They will be inducted with ... FACHE, whose induction we reported last May. , Our ... during the 2014 American Academy of Nursing Policy Conference ...
(Date:9/1/2014)... Registration is now open for the 4th Annual ... to be held on Sunday, September 21, 2014. The event ... Meadow in Secaucus, New Jersey. All proceeds from the race ... to restoring a sense of self, restoring the family unit, ... families. , General registration is $30 with special pricing for ...
(Date:9/1/2014)... San Diego, CA (PRWEB) September 01, 2014 ... website daily regarding all the latest information from the ... , The US FDA announced on August 28, ... are recalled (Class I) as the device ... FDA, the DePuy Synthes Craniomaxillofacial (CMF) Distraction System is ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 ... into Heartbeat Experts’ perspectives on stakeholder ... , Download the flash report to speak ... any launching Diabetes product:, , ... an increasingly crowded market ,     Understanding ...
(Date:8/31/2014)... 31, 2014 Just in time for Washington’s ... only wild, sustainable Alaska Salmon, award winning chowder ... Duke's Green Lake location , Sunday, September 28, 2014 ... sample several ethnic salmon BBQ culinary delights. Live music will ... from Hawaii, Puerto Rico and Mexico will be featured. ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Diabetes Products 2Health News:Seattle Seafood Restaurant Duke's Chowder House on Green Lake Will Celebrate The Long Anticipated Indian Summer With First Annual Sizzling BBQ Salmon Tasting Event. 2
... ... and Insurance Services, a leading provider of information-based technology services to the ... in Louisiana and Texas in addition to its services that are provided ... headquartered in Hampton, New Hampshire and is owned by Medical Protective, part ...
... , , ARLINGTON, Va., ... that a panel of independent scientific experts convened by the ... a reproductive or developmental toxicant. After a thorough review ... Committee determined that bisphenol A should not be listed under ...
... WASHINGTON, July 15 On behalf of the nation,s mayors, ... commended President Barack Obama, the House of Representatives and the Senate ... transformative health care reform legislation. , ... times because they are not able to afford health insurance and, ...
... , SCOTTSDALE, Ariz., July 15 Grubb ... of America, Inc.) (the "REIT"), a self-managed non-traded real estate ... agreement (the "Agreement") to acquire a 16 building portfolio from ... transaction involves approximately 855,000 square feet of medical office and ...
... , , CARY, N.C., ... CRTX ), a specialty pharmaceutical company focused on acquiring, ... and related markets, today announced that it has submitted ... Administration (FDA) for an extended-release antitussive product (CRTX 067) ...
... , , , ... presented today, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory ... and docetaxel did not provide a sufficient benefit-risk ... cancer. , , Women with locally advanced ...
Cached Medicine News:Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 2Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 3Health News:California Expert Panel Concludes Bisphenol A is Not a Reproductive or Developmental Toxicant 2Health News:The Nation's Mayors Commend New Healthcare Reform Legislation 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: